Samsung Biologics
삼성바이오로직스
World-leading CDMO for biologics manufacturing.
Latest News
Samsung Biologics Says 3 Trillion Won Rights Offering Beats Borrowing for Growth Plans
Samsung Biologics told retail investors its roughly 3 trillion won rights offering was the most efficient way to fund the Polypeptide Group acquisition and future expansion, arguing debt would strain its balance sheet as it pursues 15.4 trillion won in investments through 2034.
Samsung Biologics Defends 3.9 Trillion Won Rights Offering as Key to Long-Term Growth Plan
Samsung Biologics says its planned 3.9 trillion won ($2.8 billion) rights offering is essential to complete a roughly 15.4 trillion won investment roadmap through 2034, arguing equity is a safer funding route than debt.
Samsung Biologics' 3 Trillion Won Rights Offering Faces Test at Financial Watchdog
Samsung Biologics has launched a roughly 3 trillion won rights offering to fund its acquisition of Swiss CDMO firm PolyPeptide Group and expand production capacity, but the deal now must clear an increasingly strict review by Korea's Financial Supervisory Service.
Samsung Biologics Lands Record $1.24 Billion Deal With Asia-Based Drugmaker
Samsung Biologics has signed the largest single-client manufacturing contract in its history, a $1.24 billion agreement with an unnamed Asia-based pharmaceutical company that pushes its 2024 order backlog past $3.3 billion.
Timeline
- Samsung Biologics Says 3 Trillion Won Rights Offering Beats Borrowing for Growth Plans
- Samsung Biologics Defends 3.9 Trillion Won Rights Offering as Key to Long-Term Growth Plan
- Samsung Biologics' 3 Trillion Won Rights Offering Faces Test at Financial Watchdog
- Samsung Biologics Lands Record $1.24 Billion Deal With Asia-Based Drugmaker